tbuckley/cabot-search huggingface dataset:
POLLEN IN OIL: A PRELIMINARY REPORT ON A NEW, SLOWLY ABSORBED MEDIUM FOR USE IN HAY FEVER TREATMENT
Authors: Samuel J. Taub, Eli Rubens
Journal: Annals of Internal Medicine (1942)

Article1 October 1942POLLEN IN OIL: A PRELIMINARY REPORT ON A NEW, SLOWLY ABSORBED MEDIUM FOR USE IN HAY FEVER TREATMENTSAMUEL J. TAUB, M.D., ELI RUBENS, M.D.SAMUEL J. TAUB, M.D.Search for more papers by this author, ELI RUBENS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-17-4-642 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDunbar, in 1905, was the first to attempt pollen desensitization against hay fever. He injected horses with crude pollen, then bled the animals and used the serum on hay fever patients. It is very obvious that this treatment was unsuccessful because of horse serum reactions, and the method soon fell into bad repute.Noon, in 1911, was the first to place desensitization on a scientific basis by preparing an aqueous extract of timothy pollen. This work was further elaborated by Freeman, Koessler, Scheppegrell and Clowes. Glycero-saline extracts are still claimed to be the most stable, but when used in 50...Bibliography FLOSDORFMUDD EWS: Procedure and apparatus for preservation in "lyophile" form of serum and other biological substances, Jr. Immunol., 1935, xxix, 389-425. Google Scholar HARRISON WT: Effect of alum precipitated ragweed pollen extract, Weekly Pub. Health Rep., 1934, xlix, 462. CrossrefGoogle Scholar SPAINSAMMIS WCFE: Treatment of ragweed hay fever with ultrafiltered extracts, Jr. Allergy, 1939, vi, 357. Google Scholar CAULFIELDBROWNWATERS AHMHET: Alum as an adjuvant in sensitizing guinea pigs to ragweed pollen, Jr. Allergy, 1936, vii, 451. CrossrefGoogle Scholar KEENEYPIERCEGAY ELJALN: Epinephrine in oil, Arch. Int. Med., 1939, lxiii, 119-142. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Chicago, Illinois*Received for publication August 27, 1941.(Read at the meeting of the American Association for the Study of Allergy in Cleveland June 2, 1941.)The technical preparation of this mixture was undertaken with the assistance of Dr. S. O. Levinson of the Serum Center of Michael Reese Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1942Volume 17, Issue 4Page: 642-644KeywordsAllergy and immunologyFeversOilsPollen ePublished: 1 December 2008 Issue Published: 1 October 1942 PDF downloadLoading ...
Functional Assembly of Accessory Optic System Circuitry Critical for Compensatory Eye Movements
Authors: Lu O. Sun, Colleen M. Brady, Hugh Cahill, Timour Al-Khindi, Hiraki Sakuta, Onkar S. Dhande, Masaharu Noda, Andrew D. Huberman, Jeremy Nathans, Alex L. Kolodkin
Journal: Neuron (2015)
Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn
Authors: Krista F. Huybrechts, Brian T. Bateman, Kristin Palmsten, Rishi J. Desai, Elisabetta Patorno, Chandrasekar Gopalakrishnan, Raisa Levin, Helen Mogun, Sonia Hernandez-Diaz
Journal: JAMA (2015)

<h3>Importance</h3> The association between selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and risk of persistent pulmonary hypertension of the newborn (PPHN) has been controversial since the US Food and Drug Administration issued a public health advisory in 2006. <h3>Objective</h3> To examine the risk of PPHN associated with exposure to different antidepressant medication classes late in pregnancy. <h3>Design and Setting</h3> Cohort study nested in the 2000-2010 Medicaid Analytic eXtract for 46 US states and Washington, DC. Last follow-up date was December 31, 2010. <h3>Participants</h3> A total of 3 789 330 pregnant women enrolled in Medicaid from 2 months or fewer after the date of last menstrual period through at least 1 month after delivery. The source cohort was restricted to women with a depression diagnosis and logistic regression analysis with propensity score adjustment applied to control for potential confounders. <h3>Exposures for Observational Studies</h3> SSRI and non-SSRI monotherapy use during the 90 days before delivery vs no use. <h3>Main Outcomes and Measures</h3> Recorded diagnosis of PPHN during the first 30 days after delivery. <h3>Results</h3> A total of 128 950 women (3.4%) filled at least 1 prescription for antidepressants late in pregnancy: 102 179 (2.7%) used an SSRI and 26 771 (0.7%) a non-SSRI. Overall, 7630 infants not exposed to antidepressants were diagnosed with PPHN (20.8; 95% CI, 20.4-21.3 per 10 000 births) compared with 322 infants exposed to SSRIs (31.5; 95% CI, 28.3-35.2 per 10 000 births), and 78 infants exposed to non-SSRIs (29.1; 95% CI, 23.3-36.4 per 10 000 births). Associations between antidepressant use and PPHN were attenuated with increasing levels of confounding adjustment. For SSRIs, odds ratios were 1.51 (95% CI, 1.35-1.69) unadjusted and 1.10 (95% CI, 0.94-1.29) after restricting to women with depression and adjusting for the high-dimensional propensity score. For non-SSRIs, the odds ratios were 1.40 (95% CI, 1.12-1.75) and 1.02 (95% CI, 0.77-1.35), respectively. Upon restriction of the outcome to primary PPHN, the adjusted odds ratio for SSRIs was 1.28 (95% CI, 1.01-1.64) and for non-SSRIs 1.14 (95% CI, 0.74-1.74). <h3>Conclusions and Relevance</h3> Evidence from this large study of publicly insured pregnant women may be consistent with a potential increased risk of PPHN associated with maternal use of SSRIs in late pregnancy. However, the absolute risk was small, and the risk increase appears more modest than suggested in previous studies.
Abstract P4-15-14: Preclinical data of SYD985 support the clinical investigation of this novel anti-HER2 antibody-drug conjugate in breast cancer patients with low levels of HER2 expression
Authors: Gijs Verheijden, Patrick Beusker, Ruud Ubink, Miranda van der Lee, Patrick Groothuis, Peter Goedings, David Egging, Marco Timmers, Wim Dokter
Journal: Cancer Research (2015)

Abstract SYD985 is a novel anti-HER2 antibody-drug conjugate (ADC) in development for breast cancer. The ADC consists of three parts: i) the monoclonal antibody trastuzumab, ii) a linker that can be cleaved by tumor-resident proteases at the dipeptide valine-citrulline (vc) motif, and iii) the prodrug seco-DUocarmycin-hydroxyBenzamide-Azaindole. The average ‘drug to antibody ratio’ (DAR) of this ADC, also named trastuzumab vc-seco-DUBA, is ∼2.8. After antibody-mediated binding of SYD985 to its molecular target HER2 on the surface of tumor cells, the ADC is internalized. Subsequently, the active duocarmycin is released and binds to DNA in the minor groove, followed by alkylation of the DNA and killing of the tumor cells. In vitro and in vivo experiments were performed to (directly) compare various pharmacodynamic and pharmacokinetic properties of SYD985 with those of the most progressed (marketing-approved) HER2-targeting ADC, i.e. ado-trastuzumab emtansine (T-DM1). T-DM1 is currently indicated for second line treatment of breast cancer patients overexpressing HER2 tumor tissue. In in vitro experiments, SYD985 shows potencies similar to T-DM1 in cell lines expressing HER2 at high levels (IHC HER2 3+), whereas SYD985 is significantly more potent compared to T-DM1 in cell lines expressing low HER2 levels (IHC HER2 2+ or 1+). In line with these results, SYD985 has superior efficacy compared to T-DM1 in xenograft models in which patient-derived breast cancer tumor tissue with low HER2 levels (IHC HER2 2+ or 1+/FISH-) have been used. Pharmacokinetic experiments (in vitro and in vivo) have revealed that whereas in mice SYD985 has limited stability, in cynomolgus monkey SYD985 is very stable. Excellent stability in vitro is also observed in human plasma. Moreover, after i.v. administration of SYD985 in the cynomolgus monkey the amount of free toxin (DUBA) detected in the monkey plasma is many-fold lower than levels reported for the toxin (DM1) released from T-DM1. Resuming, the preclinical data of SYD985 support clinical studies to investigate whether SYD985 has benefit in cancer patients with moderate or even low HER2 levels of the tumor tissue. Citation Format: Gijs Verheijden, Patrick Beusker, Ruud Ubink, Miranda van der Lee, Patrick Groothuis, Peter Goedings, David Egging, Marco Timmers, Wim Dokter. Preclinical data of SYD985 support the clinical investigation of this novel anti-HER2 antibody-drug conjugate in breast cancer patients with low levels of HER2 expression [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-15-14.
Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial
Journal: Diabetes Care (2013)

OBJECTIVE The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over metformin alone (M), with metformin plus lifestyle (M+L) intermediate in maintaining glycemic control. We report here treatment effects on measures of body composition and their relationships to demographic and metabolic variables including glycemia. RESEARCH DESIGN AND METHODS Measures of adiposity (BMI, waist circumference, abdominal height, percent and absolute fat, and bone mineral content [BMC] and density [BMD]) were analyzed as change from baseline at 6 and 24 months. RESULTS Measures of fat accumulation were greatest in subjects treated with M+R and least in M+L. Although fat measures in M+L were less than those of M+R and M at 6 months, differences from M were no longer apparent at 24 months, whereas differences from M+R persisted at 24 months. The only body composition measure differing by race and/or ethnicity was waist circumference, greater in M+R than either M or M+L at both 6 and 24 months in whites. BMD and BMC increased in all groups, but increased less in M+R compared with the other two groups by 24 months. Measures of adiposity (increases in BMI, waist circumference, abdominal height, and fat) were associated with reduced insulin sensitivity and increased hemoglobin A1c (HbA1c), although effects of adiposity on HbA1c were less evident in those treated with M+R. CONCLUSIONS Despite differential effects on measures of adiposity (with M+R resulting in the most and M+L in the least fat accumulation), group differences generally were small and unrelated to treatment effects in sustaining glycemic control.
Abstract 5613: Class IIa HDAC6 Contributes to Angiogenesis and Endothelial Cell Function
Authors: David Kaluza, Carmen Urbich, Lothar Rössig, Andreas M Zeiher, Stefanie Dimmeler
Journal: Circulation (2009)

Acetylation of histone proteins contributes to the regulation of gene expression by alteration of chromatin structure. Histone deacetylases (HDACs) act as modulators of gene expression by deacetylation of histone proteins as well as non-histone proteins. Previous studies identified the class IIa histone deacetylases HDAC5 and HDAC7 as regulators of angiogenesis. The class IIb HDAC6 is the only HDAC that possesses two functional deacetylase domains and is known to be involved in lymphocyte chemotaxis and in cancer development. However, the function of HDAC6 in endothelial cells is unknown. Therefore, we analyzed the effect of HDAC6 for endothelial cell functions during angiogenesis. HDAC6 is mainly localized in the cytoplasm of human umbilical vein endothelial cells. Knockdown of HDAC6 with siRNA oligonucleotides significantly decreased endothelial cell sprouting from spheroids (42%±7, p&lt;0.05, N=5), tube formation in matrigel assay (81%±2, p&lt;0.05, N=3) and endothelial cell migration in a scratched wound assay (65%±5, p&lt;0.05, N=3) without affecting cell viability. These results were confirmed using a second unrelated oligonucleotide. Consistently, overexpression of HDAC6 wild-type increased endothelial cell sprouting (122%±8, N=4), indicating that HDAC6 is a positive regulator of angiogenesis. The catalytic activity of the second HDAC-domain seems to be necessary for the pro-angiogenic effect of HDAC6, because overexpression of a deletion mutant, which lacks the second deacetylase domain, did not affect sprouting (95%±10, N=4). Because the second HDAC-domain is known to be responsible for α -tubulin deacetylation and acetylation of α -tubulin might play a role in cell migration, we assessed the effect of the HDAC6 specific tubulin deacetylation inhibitor tubacin on endothelial sprout formation. Application of tubacin did not affect sprouting, indicating that the mechanism is independent of α -tubulin deacetylation. In summary, we found that the cytoplasmic HDAC6 is necessary for in vitro angiogenesis as assessed by endothelial sprouting, tube formation and migration. Mechanistically, the pro-angiogenic effect of HDAC6 in endothelial cells requires the second deacetylase domain, but is independent of α -tubulin deacetylation.
Adiponectin Enhances Cold-Induced Browning of Subcutaneous Adipose Tissue via Promoting M2 Macrophage Proliferation
Authors: Xiaoyan Hui, Ping Gu, Jialiang Zhang, Tao Nie, Yong Pan, Donghai Wu, Tianshi Feng, Cheng Zhong, Yu Wang, Karen S.L. Lam, Aimin Xu
Journal: Cell Metabolism (2015)
Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease?
Authors: Yoram Agmon, Bijoy K Khandheria, Irene Meissner, JoRean D Sicks, W.Michael O’Fallon, David O Wiebers, Jack P Whisnant, James B Seward, A.Jamil Tajik
Journal: Journal of the American College of Cardiology (2001)
Human immunodeficiency virus-related conditions in children and adults with hemophilia: rates, relationship to CD4 counts, and predictive value
Authors: ME Eyster, CS Rabkin, MW Hilgartner, LM Aledort, MV Ragni, J Sprandio, GC White, S Eichinger, P de Moerloose, WA Andes
Journal: Blood (1993)
Abstract 565: Telomerase reverse transcriptase promoter alterations in human bladder cancer
Authors: Sevilay Turan
Journal: Cancer Research (2014)

Abstract The telomerase reverse transcriptase (TERT) gene encodes the catalytic subunit of the enzyme telomerase, (aka telomere terminal transferase), which contains both protein and RNA subunits. TERT is a RNA-dependent polymerase which increases the length of telomeres at the ends of each chromosome by adding TTAGGG repeats. TERT polymerase uses RNA as a complementary primer to elongate telomeric G-rich repeat sequences in the 5’ to 3’ direction. TERT is essential and active in germ cells, stem cells, primary tumors, and immortalized cells and acts to maintain adequate telomeres. However, in somatic cells, TERT expression is reduced or absent and telomeres gradually shorten during the S phase of each cell cycle due to replication-dependent loss of telomere terminal sequences. Adequate telomere length is important for preserving genome stability, regulating cell replication, and preventing cell death. Somatic TERT promoter alterations were recently reported in melanoma, glioma, and in small sample sets from other cancers including bladder cancer. These are thought to drive re-expression of TERT in cancer cells. In this study, given recent reports of somatic TERT promoter alterations in bladder cancer, polymerase chain reaction and Sanger sequencing were performed to examine a region of the TERT promoter in 58 bladder tumors. The TERT promoter was altered in 90% of 58 tumors by 44 germline (21 unique, 20 novel) and 53 somatic variants (11 unique, 4 novel). Somatic alterations were observed in 67% of tumors. The majority of variants were C&amp;gt;T DNA changes, three variants occurred as both germline and somatic, and a subset of variants created or altered transcription factor binding sites and promoter CpGs. Analyses of telomere length showed significantly shorter telomeres in tumor tissue versus adjacent normal tissue from the same patient (p=0.004) indicating TERT may not sufficiently lengthen telomeres in rapidly proliferating cancer cells. Interestingly, somatic TERT promoter alterations were not associated with stage, grade, or alterations in other bladder cancer genes identified by exome sequencing. We speculate that TERT promoter alterations are frequent and early events in bladder cancer and identification of TERT alterations in urine may provide a biomarker for early diagnosis and monitoring of bladder cancer. Note: This abstract was not presented at the meeting. Citation Format: Sevilay Turan. Telomerase reverse transcriptase promoter alterations in human bladder cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 565. doi:10.1158/1538-7445.AM2014-565
Still Life With Fruit
Authors: M. Therese Southgate
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification of the gene responsible for Best macular dystrophy
Authors: Konstantin Petrukhin, Markus J. Koisti, Benjamin Bakall, Wen Li, Guochun Xie, Towa Marknell, Ola Sandgren, Kristina Forsman, Gösta Holmgren, Sten Andreasson, Mihailo Vujic, Arthur A. B. Bergen, Valarie McGarty-Dugan, David Figueroa, Christopher P. Austin, Michael L. Metzker, C.Thomas Caskey, Claes Wadelius
Journal: Nature Genetics (1998)
High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study
Authors: E. Christensen, C. Mørk, E. Skogvoll
Journal: British Journal of Dermatology (2012)

Prolonged follow-up data on topical photodynamic therapy (PDT) in basal cell carcinoma (BCC) are necessary for a full evaluation of its effect and for comparison with conventional treatment methods.To assess 10-year long-term PDT efficacy in primary and recurrent BCC and to evaluate clinical and histopathological factors which may be associated with treatment failure.We performed a longitudinal study on 60 histologically verified BCCs in 44 patients treated with curettage and one or two sessions of dimethylsulphoxide (DMSO)-supported topical 5-aminolaevulinic acid (ALA)-based PDT. Treated lesions were investigated by clinical and histopathological examination at regular intervals. The main outcomes were 10-year lesion complete response rate using a time-to-event analysis, histological treatment failure and cosmesis.Overall complete response rate for all lesions was 75% (95% confidence interval 64-87%); 60% after one and 87% after two treatment sessions. The response rate was 78% for primary lesions; 63% after one and 90% after two sessions. The cosmetic outcome was rated as good or excellent in 91-100% of evaluated cases. Treatment failure was documented in 15 (25%) of 60 lesions; clinical investigation identified 14 of them. All failures were noted within 3 years of treatment. Male gender, recurrent tumour and one treatment session were factors significantly associated with treatment failure. The only lesion larger than 2·0 cm relapsed.Two sessions of DMSO-supported topical ALA-PDT and curettage can provide long-term effective treatment results with favourable cosmetic outcome in primary, small BCC.
Schizophrenia and smoking: an epidemiological survey in a state hospital
Authors: J de Leon, M Dadvand, C Canuso, A O White, J K Stanilla, G M Simpson
Journal: American Journal of Psychiatry (1995)

The authors sought to determine whether smoking is related to schizophrenia or neuroleptic treatment.Cigarette smoking was measured in all patients hospitalized at a state hospital (N = 360) and compared in relation to gender and diagnosis (schizophrenic versus nonschizophrenic).The overall frequency of smoking was 79% (N = 284). Male schizophrenic patients had the highest frequency of smoking, followed by male nonschizophrenic patients, female schizophrenic patients, and female nonschizophrenic patients, respectively. Schizophrenia and polydipsia were associated with both smoking and heavy smoking.After correction for other variables, schizophrenia appears to increase the risk of being both a smoker and a heavy smoker. There was a possible association between high doses of neuroleptics and smoking but only for nonschizophrenic patients.
Polyoma Virus and Production of Malignancy &lt;italic&gt;In Vitro&lt;/italic&gt;
Authors: Katherine K. Sanford, Thelma B. Dunn, Anne B. Covalesky, Lartius T. Dupree, Wilton R. Earle
Journal: JNCI Journal of the National Cancer Institute (1961)

Journal Article Polyoma Virus and Production of Malignancy In Vitro Get access Katherine K. Sanford, Katherine K. Sanford Laboratory of Biology, National Cancer Institute,3, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Thelma B. Dunn, Thelma B. Dunn Laboratory of Biology, National Cancer Institute,3, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Anne B. Covalesky, Anne B. Covalesky Laboratory of Biology, National Cancer Institute,3, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Lartius T. Dupree, Lartius T. Dupree Laboratory of Biology, National Cancer Institute,3, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Wilton R. Earle Wilton R. Earle Laboratory of Biology, National Cancer Institute,3, Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 26, Issue 2, February 1961, Pages 331–357, https://doi.org/10.1093/jnci/26.2.331 Published: 01 February 1961 Article history Received: 03 August 1960 Published: 01 February 1961